Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Insiders Buying Outlook Therapeutics And 2 Other Stocks

Published 01/04/2024, 15:46
Updated 01/04/2024, 17:11
© Reuters.  Insiders Buying Outlook Therapeutics And 2 Other Stocks

Benzinga - by Avi Kapoor, Benzinga Staff Writer.

Although U.S. stocks closed mixed on Thursday, there were a few notable insider trades.

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.

Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.

CION Investment

  • The Trade: CION Investment Corporation (NYSE: CION) Co-Chairman & Co-CEO Mark Gatto acquired a total of 1,150 shares an average price of $11.02. To acquire these shares, it cost around $12,673.
  • What’s Happening: On March 14, CION Invt posted downbeat quarterly earnings
  • What CION Investment Does: CION Investment is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company.
Outlook Therapeutics
  • The Trade: Outlook Therapeutics, Inc. (NASDAQ: OTLK) Director Yezan Munther Haddadin acquired a total of 1,881 shares at an average price of $11.82. To acquire these shares, it cost around $22,242.
  • What’s Happening: On March 27, BTIG upgraded the stock from Neutral to Buy and announced a $50 price target.
  • What Outlook Therapeutics Does: Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Rocket Companies

  • The Trade: Rocket Companies, Inc. (NYSE: RKT) Director Matthew Rizik bought a total of 301 shares at an average price of $14.57. To acquire these shares, it cost around $4,386.
  • What’s Happening: On March 18, B of A Securities analyst Mihir Bhatia maintained Rocket Companies with an Underperform and raised the price target from $7 to $8.
  • What Rocket Companies Does: Rocket Companies is a financial services company that was originally founded as Rock Financial in 1985 and is currently based in Detroit.

Check This Out: How To Earn $500 A Month From Verizon Stock On Heels Of Analyst Upgrade

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.